TNSN01036A1 - 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASES - Google Patents
5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASESInfo
- Publication number
- TNSN01036A1 TNSN01036A1 TNTNSN01036A TNSN01036A TNSN01036A1 TN SN01036 A1 TNSN01036 A1 TN SN01036A1 TN TNSN01036 A TNTNSN01036 A TN TNSN01036A TN SN01036 A TNSN01036 A TN SN01036A TN SN01036 A1 TNSN01036 A1 TN SN01036A1
- Authority
- TN
- Tunisia
- Prior art keywords
- lower alkyl
- mqr4
- co2r4
- halogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
DISCLOSED ARE COMPOUNDS OF THE FORMULA WHERE IN : R2 IS HYDROGEN, ALKYL, OR CYCLOALKYL ; R3 IS HYDROGEN, LOWER ALKYL, LOWER ALKOXY, HALOGEN, TRIFLUOROMETHYL, LOWER ALKYNYL, LOWER ALKENYL, NITRILE, NITRO, -COR4, -CO2R4, -CONR4R5, -CONR4OR5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), Y IS N OR CR7 ; R9 IS LOWER ALKYL, HALOALKYL, OR ARYL ; X AND Z ARE INDEPENDENTLY HYDROGEN, HALOGEN, LOWER ALKYL, LOWER ALKOXY,TRIFLUOROMETHYL, HYDROXY, NITRILE, NITRO, -NR4R5, -N(O)R4R5, -NR4R5R6W, -SR4, -C(O)R4, -CO2R4, -CONR4R5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), -T(CH2)mQR4, -C(O)T(CH2)mQR4, OR –NR4C(O)T(CH2)mQR5 ; m IS 1 TO 6 ; T IS O, S, NR4, N(O)R4, NR4R5W, OR CR4R5 ; Q IS O, S, NR4, N(O)R4, NR4R5W, CO2, OR A CARBOCYCLIC GROUP CONTAINING FROM 3 TO 7 MEMBERS, UP TO FOUR OF WHICH MEMBERS ARE OPTIONALLY HETEROATOMS INDEPENDENTLY SELECTED FROM OXYGEN, SULFUR, AND NITROGEN, WHEREIN THE CARBOCYCLIC GROUP IS UNSUBSTITUTED OR SUBSTITUTED WITH ONE, TWO, OR THREE GROUPS INDEPENDENTLY SELECTED FROM HALOGEN, HYDROXY, HYDROXYALKYL, LOWER ALKYL, LOWER ALKOXY ALKOXYCARBONYL, ALKYLCARBONYL, ALKYLCARBONYLAMINO, AMINOALKYL, TRIFLUOROMETHYL, N-HYDROXYACETAMIDE, TRIFLUOROMETHYLALKYL, AMINO, OR MONO OR DIALKYLAMINO ; R6 LOWER ALYL, HALOALKYL OR ARYL; R7 IS –NR4R5, -N(O)R4R5, -NR4R5R9X, -OH, -OR4, -SR4, HALO, -COR4, (CH2)nR4, CO2R4, CONR4R5, -C(O)NR4SO2R5, -S(O)R4, -SO2R4, -SO2NR4R5, -SO3R4, -(CH2)nP(O)(OR4)2, -NR4SO2R5, ALDEHYDE, NITRILE, NITRO, ALKYL ALKOXYALKYL, -T(CH2)mQR4, -C(O)T(CH2)mQR4, -NR4C(O)T(CH2)mQR5, OR –T(CH2)CO2R4 ; n IS 0 TO 6 ; W IS AN ANION ; R4 AND R5 ARE INDEPENDENTLY HYDROGEN, LOWER ALKYL, LOWER ALKENYL, LOWER ALKYNYL, (CH2) nAr, ARYLALKYL, ARYL, HETEROARYL, HETEROARYLALKYL, CYCLOALKYL, HETEROCYCLOALKYL, OR HETEROARYL, OR R4 AND R5 TOGETHER WITH THE NITROGEN TO WHICH THEY ARE ATTACHED FORM A CARBOCYCLIC RING CONTAINING 3 TO 8 MEMBERS, UP TO FOUR OF WHICH MEMBERS ARE OPTIONALLY CARBONYL GROUPS OR HETEROATOMS INDEPENDENTLY SELECTED FROM O, S, SO, S(O)2, AND N; AND WHEN Y IS CR7 , IT IS PART OF THE PORT STRUCTURE …….. WHEREIN R7 AND Z ARE AS DEFINED ABOVE, OR CAN BE TAKEN TOGETHER WITH THE CARBONS TO WHICH THEY ARE ATTACHED TO FORM… WHEREIN : G AND J ARE INDEPENDENTLY CH2, NH, OR O; B IS NH, S, CH2, OR O; D IS C OR N, PROVIDED THAT R10 IS NOTHING WHEN D IS N; AND R10 AND R11 ARE INDEPENDENTLY HYDROGEN, HALOGEN, LOWER ALKYL, LOWER ALKOXY, OR ALKYLCARBONYL; THESE COMPOUNDS ARE USEFUL FOR TREATING CELL PROLIFERATIVE DISORDERS, SUCH AS CANCER, ATHEROSCLEROSIS, AND RESTENOSIS. THESE COMPOUNDS ARE POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) AND GROWTH FACTOR-MEDIATED KINASES; THE PRESENT INVENTION ALSO PROVIDES A METHOD OF TREATING CELL PROLIFERATIVE DISORDERS; ALSO PROVIDED BY THE PRESENT INVENTION IS A PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND OF FORMULA I TOGETHER WITH A CARRIER OR EXCIPIENT
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18712400P | 2000-03-06 | 2000-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN01036A1 true TNSN01036A1 (en) | 2005-11-10 |
Family
ID=22687699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN01036A TNSN01036A1 (en) | 2000-03-06 | 2001-03-02 | 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASES |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1268476A1 (en) |
| JP (1) | JP2003528101A (en) |
| KR (1) | KR20020075805A (en) |
| CN (1) | CN1422268A (en) |
| AP (1) | AP2002002643A0 (en) |
| AR (1) | AR034119A1 (en) |
| AU (1) | AU2001233028A1 (en) |
| BG (1) | BG107161A (en) |
| BR (1) | BR0109056A (en) |
| CA (1) | CA2401368A1 (en) |
| CO (1) | CO5280200A1 (en) |
| CR (1) | CR6736A (en) |
| CZ (1) | CZ20022929A3 (en) |
| DZ (1) | DZ3308A1 (en) |
| EA (1) | EA200200802A1 (en) |
| EE (1) | EE200200506A (en) |
| GT (1) | GT200100037A (en) |
| HN (1) | HN2001000040A (en) |
| HR (1) | HRP20020798A2 (en) |
| HU (1) | HUP0300136A2 (en) |
| IL (1) | IL151480A0 (en) |
| IS (1) | IS6524A (en) |
| MA (1) | MA26881A1 (en) |
| MX (1) | MXPA02008535A (en) |
| NO (1) | NO20024235L (en) |
| NZ (1) | NZ520962A (en) |
| OA (1) | OA12227A (en) |
| PA (1) | PA8513201A1 (en) |
| PE (1) | PE20011177A1 (en) |
| PL (1) | PL358271A1 (en) |
| SK (1) | SK12472002A3 (en) |
| SV (1) | SV2001000338A (en) |
| TN (1) | TNSN01036A1 (en) |
| WO (1) | WO2001070741A1 (en) |
| YU (1) | YU66502A (en) |
| ZA (1) | ZA200207110B (en) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| BR0114829A (en) | 2000-10-23 | 2003-09-23 | Smithkline Beecham Corp | New compounds |
| WO2002064594A2 (en) * | 2001-02-12 | 2002-08-22 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| NZ527741A (en) | 2001-02-26 | 2005-02-25 | Tanabe Seiyaku Co | Pyridopyrimidine or naphthyridine derivative |
| US20030105115A1 (en) * | 2001-06-21 | 2003-06-05 | Metcalf Chester A. | Novel pyridopyrimidines and uses thereof |
| EP1408985A4 (en) * | 2001-06-21 | 2006-03-22 | Ariad Pharma Inc | Novel pyridopyrimidones and uses thereof |
| PL220952B1 (en) * | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pyridin-2-ylamino) pyrido [2,3-d] pyrimidin -7-ones |
| JP4603268B2 (en) | 2002-04-19 | 2010-12-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | New compounds |
| CA2494061C (en) | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| AU2003273675A1 (en) | 2002-10-09 | 2004-05-04 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| BRPI0406809A (en) * | 2003-01-17 | 2005-12-27 | Warner Lambert Co | 2-Aminopyridine substituted heterocycles as cell proliferation inhibitors |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| ATE412650T1 (en) * | 2003-07-11 | 2008-11-15 | Warner Lambert Co | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR |
| US8362017B2 (en) | 2003-08-29 | 2013-01-29 | Exelixis, Inc. | C-kit modulators and methods of use |
| EP1685131B1 (en) | 2003-11-13 | 2007-03-07 | F. Hoffmann-La Roche AG | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
| DE102004029784A1 (en) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments |
| DE102004033670A1 (en) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pyridodihydropyrazinone, process for its preparation and its use as a medicament |
| FR2873118B1 (en) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| EP1630163A1 (en) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, methods for their preparation and their use as drugs |
| JP2008510770A (en) * | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel pteridinone as a PLK inhibitor |
| DE102004058337A1 (en) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of fused piperazin-2-one derivatives |
| WO2006076706A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
| US7423042B2 (en) | 2005-03-25 | 2008-09-09 | Glaxo Group Limited | Compounds |
| TWI389690B (en) | 2005-03-25 | 2013-03-21 | Glaxo Group Ltd | Novel compounds |
| WO2006104917A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives |
| TW200724142A (en) | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
| US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| FR2887882B1 (en) | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
| GEP20115304B (en) | 2005-10-07 | 2011-10-10 | Exelixis Inc | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
| CA2624965A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
| FR2896246B1 (en) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| ES2366489T3 (en) | 2006-09-15 | 2011-10-20 | Pfizer Products Inc. | PIRID COMPOUND (2,3-D) PIRIDINONE AND ITS USE AS PI3 INHIBITORS. |
| CA2665384A1 (en) * | 2006-10-16 | 2008-04-24 | Gpc Biotech Inc. | Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2008055013A2 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| FR2910813B1 (en) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA |
| RU2467008C2 (en) * | 2007-04-03 | 2012-11-20 | Эррэй Биофарма Инк. | IMIDAZO[1, 2-a]PYRIDINE COMPOUNDS AS INHIBITORS OF RECEPTOR TYROSINKINASES |
| HRP20161536T1 (en) * | 2007-06-15 | 2016-12-30 | Msd K.K. | Bicycloaniline derivative |
| CA2695406A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| NZ586069A (en) | 2007-12-19 | 2012-05-25 | Amgen Inc | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| CA2710039C (en) | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
| EP2100894A1 (en) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| ATE531372T1 (en) * | 2008-04-07 | 2011-11-15 | Amgen Inc | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINOPYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| EP2350070A1 (en) | 2008-09-30 | 2011-08-03 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k and mtor |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| CA2776770A1 (en) * | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| JP5797664B2 (en) * | 2009-12-18 | 2015-10-21 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ | Substituted pyrido [2,3-d] pyrimidin-7 (8H) -ones and their therapeutic use |
| TW201139436A (en) | 2010-02-09 | 2011-11-16 | Exelixis Inc | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
| US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| EA022527B1 (en) * | 2010-08-05 | 2016-01-29 | Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE-6-CARBONITRILES AND USES THEREOF |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| ES2620521T3 (en) | 2011-03-23 | 2017-06-28 | Amgen Inc. | Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3 |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| US8962831B2 (en) * | 2011-05-17 | 2015-02-24 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US9718821B2 (en) | 2012-02-23 | 2017-08-01 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| ES2694787T3 (en) * | 2013-02-21 | 2018-12-27 | Pfizer Inc. | Solid forms of a selective CDK4 / 6 inhibitor |
| JP2016525532A (en) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Treatment of myelodysplastic syndrome |
| WO2016015598A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| TWI646094B (en) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| MA45920B1 (en) | 2016-08-15 | 2021-08-31 | Pfizer | Pyridopyrimidinone cdk2 / 4/6 inhibitors |
| CN110809576B (en) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | FGFR kinase inhibitor and pharmaceutical use |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| TW202035406A (en) | 2018-12-07 | 2020-10-01 | 大陸商杭州英創醫藥科技有限公司 | Heterocyclic compounds as CDK-HDAC dual pathway inhibitors |
| CN112759589B (en) * | 2019-11-01 | 2022-04-08 | 暨南大学 | Pyrimidopyridinones and their use |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| AU2022234998B2 (en) * | 2021-03-08 | 2025-04-10 | Jinan University | Pyridopyrimidine compounds and applications thereof |
| WO2022258023A1 (en) * | 2021-06-09 | 2022-12-15 | 郑州同源康医药有限公司 | Compound as cdk kinase inhibitor and use thereof |
| US20250388576A1 (en) * | 2022-09-16 | 2025-12-25 | East China Normal University | Pyridonopyrimidine derivative as rsk inhibitor and use thereof |
| WO2024099403A1 (en) * | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| ES2301194T3 (en) * | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | PIRIDO 2,3-D PYRIMIDINS AND 4-AMINOPIRIMIDINAS AS INHIBITORS OF THE CELL PROLIFERATION. |
| EA003640B1 (en) * | 1998-05-26 | 2003-08-28 | Варнер-Ламберт Компани | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
-
2001
- 2001-01-29 OA OA1200200281A patent/OA12227A/en unknown
- 2001-01-29 NZ NZ520962A patent/NZ520962A/en unknown
- 2001-01-29 KR KR1020027011627A patent/KR20020075805A/en not_active Withdrawn
- 2001-01-29 EA EA200200802A patent/EA200200802A1/en unknown
- 2001-01-29 HR HR20020798A patent/HRP20020798A2/en not_active Application Discontinuation
- 2001-01-29 IL IL15148001A patent/IL151480A0/en unknown
- 2001-01-29 MX MXPA02008535A patent/MXPA02008535A/en not_active Application Discontinuation
- 2001-01-29 CA CA002401368A patent/CA2401368A1/en not_active Abandoned
- 2001-01-29 HU HU0300136A patent/HUP0300136A2/en unknown
- 2001-01-29 DZ DZ013308A patent/DZ3308A1/en active
- 2001-01-29 PL PL01358271A patent/PL358271A1/en not_active Application Discontinuation
- 2001-01-29 EP EP01905114A patent/EP1268476A1/en not_active Withdrawn
- 2001-01-29 WO PCT/US2001/002657 patent/WO2001070741A1/en not_active Ceased
- 2001-01-29 YU YU66502A patent/YU66502A/en unknown
- 2001-01-29 AP APAP/P/2002/002643A patent/AP2002002643A0/en unknown
- 2001-01-29 AU AU2001233028A patent/AU2001233028A1/en not_active Abandoned
- 2001-01-29 CN CN01807590A patent/CN1422268A/en active Pending
- 2001-01-29 EE EEP200200506A patent/EE200200506A/en unknown
- 2001-01-29 CZ CZ20022929A patent/CZ20022929A3/en unknown
- 2001-01-29 JP JP2001568942A patent/JP2003528101A/en not_active Abandoned
- 2001-01-29 BR BR0109056-9A patent/BR0109056A/en not_active IP Right Cessation
- 2001-01-29 SK SK1247-2002A patent/SK12472002A3/en unknown
- 2001-03-02 TN TNTNSN01036A patent/TNSN01036A1/en unknown
- 2001-03-05 PA PA20018513201A patent/PA8513201A1/en unknown
- 2001-03-05 PE PE2001000216A patent/PE20011177A1/en not_active Application Discontinuation
- 2001-03-05 CO CO01017398A patent/CO5280200A1/en not_active Application Discontinuation
- 2001-03-05 SV SV2001000338A patent/SV2001000338A/en not_active Application Discontinuation
- 2001-03-05 AR ARP010101039A patent/AR034119A1/en unknown
- 2001-03-05 HN HN2001000040A patent/HN2001000040A/en unknown
- 2001-03-05 GT GT200100037A patent/GT200100037A/en unknown
-
2002
- 2002-08-23 IS IS6524A patent/IS6524A/en unknown
- 2002-08-23 CR CR6736A patent/CR6736A/en not_active Application Discontinuation
- 2002-09-04 MA MA26801A patent/MA26881A1/en unknown
- 2002-09-04 ZA ZA200207110A patent/ZA200207110B/en unknown
- 2002-09-05 NO NO20024235A patent/NO20024235L/en not_active Application Discontinuation
- 2002-10-02 BG BG107161A patent/BG107161A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN01036A1 (en) | 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASES | |
| RU2376287C2 (en) | Derivatives of benzamide, method of their production and their application, pharmaceutical composition and method for provision of inhibiting action in respect to hdac | |
| YU73300A (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydro-pyrimidines as inhibitors of cellular proliferation | |
| NZ591712A (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| NZ333706A (en) | Benzenesulfone derivatives and medicaments | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| TW200517109A (en) | Substituted pyridinones | |
| YU18502A (en) | Pteridinones as kinase inhibitors | |
| MY118109A (en) | Novel aralkyl amines of spirofuropyridines useful in therapy | |
| GEP20043214B (en) | Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same | |
| MXPA05013349A (en) | 2-aminopyrimidine derivatives as raf kinase inhibitors. | |
| MY111446A (en) | Pyrazolopyrimidinones for the treatment of impotence | |
| SI3106463T1 (en) | Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors | |
| BR0108456A (en) | Compound, use of a compound, methods of treatment or prophylaxis of psychotic disorders or disorders of intellectual impairment and human diseases, and, process for preparing a compound | |
| PL368409A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a? receptor and their use as medicaments | |
| NZ527249A (en) | Purine derivatives as purinergic receptor antagonists | |
| CA2461916A1 (en) | Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis | |
| MXPA04000407A (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents. | |
| ATE401080T1 (en) | (3-((CHINAZOLINE-4-YL)AMINO)-1H-PYRAZOLE-1- YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | |
| MX2020013847A (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof. | |
| ZA9811645B (en) | Acronycine compounds a process for their preparation and pharmaceutical compositions containing them | |
| RU2007120691A (en) | NICOTINAMIDOPYRIDIN UREA AS VINCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | |
| ATE397609T1 (en) | CORTICOTROPINE RELEASE FACTOR ANTAGONISTS | |
| WO2002087587A3 (en) | 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors | |
| WO2005019193A3 (en) | Phenylurea derivatives useful in the treatment of conditions mediated by polo-like kinases (plk) |